Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to Post Q3 2024 Earnings of $0.45 Per Share, Zacks Research Forecasts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Equities researchers at Zacks Research raised their Q3 2024 earnings per share estimates for Catalyst Pharmaceuticals in a report issued on Wednesday, August 28th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $0.45 per share for the quarter, up from their prior estimate of $0.43. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.82 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q4 2024 earnings at $0.48 EPS, FY2024 earnings at $1.79 EPS, Q2 2025 earnings at $0.50 EPS, Q3 2025 earnings at $0.49 EPS, Q4 2025 earnings at $0.54 EPS, FY2025 earnings at $1.99 EPS, Q2 2026 earnings at $0.61 EPS and FY2026 earnings at $2.30 EPS.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The business had revenue of $122.71 million during the quarter, compared to the consensus estimate of $111.76 million.

Several other equities analysts also recently issued reports on CPRX. Citigroup upped their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th. HC Wainwright lifted their price target on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a report on Monday, August 12th. Oppenheimer reissued an “outperform” rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, June 6th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Truist Financial raised their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus target price of $29.50.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $19.74 on Monday. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of 36.56, a price-to-earnings-growth ratio of 3.30 and a beta of 0.70. The stock’s fifty day moving average is $17.71 and its two-hundred day moving average is $16.35. Catalyst Pharmaceuticals has a fifty-two week low of $11.55 and a fifty-two week high of $20.87.

Institutional Trading of Catalyst Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its position in Catalyst Pharmaceuticals by 72.9% in the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 819 shares during the period. CWM LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 3,549 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Catalyst Pharmaceuticals during the 2nd quarter worth approximately $70,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Catalyst Pharmaceuticals in the 2nd quarter valued at $153,000. Finally, Headlands Technologies LLC bought a new stake in shares of Catalyst Pharmaceuticals during the first quarter worth $154,000. Institutional investors own 79.22% of the company’s stock.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 150,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the sale, the insider now directly owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Carmen Jeffrey Del sold 7,541 shares of the company’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $16.07, for a total transaction of $121,183.87. Following the completion of the sale, the insider now owns 18,427 shares in the company, valued at approximately $296,121.89. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Steve Miller sold 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the sale, the insider now owns 675,124 shares of the company’s stock, valued at $13,738,773.40. The disclosure for this sale can be found here. Insiders have sold a total of 208,599 shares of company stock valued at $4,139,372 over the last ninety days. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.